GlassScriptPhysician profile
Michael V Verdi
NPI 1063559029
$3,208.35
in general payments reported to CMS, 2019-2025
31 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $90.65 · 2021: $178 · 2022: $675 · 2023: $1,067 · 2024: $140 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264 · Long Term Medical Supply Or Device Loan: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.77 |
| Long Term Medical Supply Or Device Loan | $332.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $718.22 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $558.21 | 2019-2025 | Collagenase Santyl, Regranex, Stravix Pl |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $283.52 | 2019-2024 | Jublia |
| Cashflow Solutions, LLC | $181.56 | 2022 | |
| Organogenesis INC. | $138.50 | 2019-2023 | Puraply |
| Accufix Surgical INC. | $132.29 | 2023 | Accu-Joint |
| Stryker Corporation | $131.03 | 2023-2025 | Augment Injectable, Easyfuse, 7 X 23mm Citrelock Implant |
| Abbvie INC. | $124.88 | 2021-2023 | Dalvance |
| Paratek Pharmaceuticals, INC. | $96.39 | 2023-2025 | Nuzyra |
| Treace Medical Concepts, INC. | $87.96 | 2022-2023 | |
| Sandoz INC. | $82.50 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $79.84 | 2019-2023 | Naftin |
| Merck Sharp & Dohme LLC | $68.68 | 2019 | |
| Melinta Therapeutics, LLC | $55.47 | 2019 | |
| Horizon Therapeutics Plc | $53.18 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $47.45 | 2023-2024 | |
| Boston Scientific Corporation | $39.64 | 2019-2022 | |
| Paragon 28, INC. | $33.74 | 2021-2023 | Phantom Metatarsal Shortening |
| Medshape, INC. | $31.33 | 2023 | Dynanail Helix, Washer, 15 Mm |
| Vertex Pharmaceuticals Incorporated | $30.78 | 2025 | |
| Polynovo North America LLC | $30.45 | 2022 | |
| Dynasplint Systems INC. | $28.99 | 2019-2024 | Dynasplint |
| Heron Therapeutics, INC. | $28.70 | 2021-2022 | |
| Alfasigma USA, INC. | $24.31 | 2021 | |
| Abbott Laboratories | $23.08 | 2019 | |
| Kerecis Limited | $21.73 | 2020 | |
| Ani Pharmaceuticals, INC. | $18.98 | 2025 | Oxistat |
| Royal Biologics, INC. | $18.74 | 2020 | |
| Ibsa Pharma INC. | $13.07 | 2023 | Tirosint, Licart |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Wright Medical Technology, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Verdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.